RNA polymerase II subunit A C-terminal domain phosphatase; TFIIF-associating CTD phosphatase; CTDP1; FCP1

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit Ig

Rabbit

This CTDP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 247-276 amino acids from the N-terminal region of human CTDP1.

Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Vial Concentration: 0.5 (lot specific)

Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.

Small volumes of anti-CTDP1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

CTDP1 is a protein which interacts with the carboxy-terminus of transcription initiation factor TFIIF, a transcription factor which regulates elongation as well as initiation by RNA polymerase II. The protein may also represent a component of an RNA polymerase II holoenzyme complex.

Signal Transduction

Western Blot (WB), ELISA (EIA), Immunohistochemistry (IHC), Flow Cytometry (FC/FACS)

WB~~1:1000

Western blot analysis of CTDP1 Antibody (N-term) in 293 cell line lysates (35ug/lane). CTDP1 (arrow) was detected using the purified Pab.

Formalin-fixed and paraffin-embedded human brain tissue with CTDP1 Antibody (N-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

Flow cytometric analysis of WiDr cells using CTDP1 Antibody (N-term)(bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

104399

CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1

RNA polymerase II subunit A C-terminal domain phosphatase

RNA polymerase II subunit A C-terminal domain phosphatase

FCP1??[Similar Products]

CTDP1_HUMAN

This gene encodes a protein which interacts with the carboxy-terminus of the RAP74 subunit of transcription initiation factor TFIIF, and functions as a phosphatase that processively dephosphorylates the C-terminus of POLR2A (a subunit of RNA polymerase II), making it available for initiation of gene expression. Mutations in this gene are associated with congenital cataracts, facial dysmorphism and neuropathy syndrome (CCFDN). Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Feb 2011]

CTDP1: a phospho-serine/threonine protein phosphatase which interacts with the carboxy-terminus of transcription initiation factor TFIIF-alpha, a transcription factor which regulates elongation as well as initiation by RNA polymerase II. Its phosphorylation increases binding to TFIIF-alpha, affecting transcription elongation. Alternative splicing results in two different isoforms.

Protein type: Transcription initiation complex; Motility/polarity/chemotaxis; Protein phosphatase, Ser/Thr (non-receptor); EC 3.1.3.16

Chromosomal Location of Human Ortholog: 18q23

Cellular Component: nucleoplasm; spindle pole; centrosome; cytoplasm; spindle; midbody; spindle midzone; actin cytoskeleton

Molecular Function: DNA-directed RNA polymerase activity; CTD phosphatase activity

Biological Process: transcription from RNA polymerase II promoter; viral reproduction; positive regulation of viral transcription; cell division; RNA elongation from RNA polymerase II promoter; gene expression; protein amino acid dephosphorylation; exit from mitosis

Disease: Congenital Cataracts, Facial Dysmorphism, And Neuropathy

Hirose,Y., Biochem. Biophys. Res. Commun. 369 (2), 449-455 (2008)
Abbott,K.L., Biochemistry 44 (8), 2716-2731 (2005)

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.